MoonLake Immunotherapeutics
MLTXHeld by 9 specialist biotech funds
High Convergence9 funds opened new positions. Next phase3 readout (Sonelokimab): Jun 2025. Short interest: 12.8% of float.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.